Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 654 | 641 | 660 | 466 | 312 |
| Cost of Goods | 461 | 322 | 364 | 120 | 262 |
| Gross Profit | 193 | 319 | 296 | 346 | 50 |
| Operating Expenses | 8,555 | 7,437 | 4,442 | 7,563 | 8,319 |
| Operating Income | -7,901 | -6,796 | -3,782 | -7,097 | -8,007 |
| Interest Expense | 247 | 538 | -169 | 255 | 2,153 |
| Other Income | 391 | 308 | -163 | 194 | 444 |
| Pre-tax Income | -7,757 | -7,026 | -3,776 | -7,158 | -9,716 |
| Income Tax | 21 | -45 | 45 | 5 | 38 |
| Net Income Continuous | -7,778 | -6,981 | -3,821 | -7,163 | -9,754 |
| Minority Interests | -755 | -710 | -823 | -619 | -933 |
| Net Income | $-7,023 | $-6,271 | $-2,998 | $-6,544 | $-8,821 |
| EPS Basic Total Ops | -1.68 | -1.50 | -0.80 | -1.60 | -2.10 |
| EPS Basic Continuous Ops | -1.86 | -1.68 | -0.93 | -1.74 | -2.37 |
| EPS Diluted Total Ops | -1.68 | -1.50 | -0.80 | -1.60 | -2.10 |
| EPS Diluted Continuous Ops | -1.86 | -1.68 | -0.93 | -1.74 | -2.37 |
| EBITDA(a) | $-7,254 | $-6,155 | $-3,141 | $-6,452 | $-7,394 |